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ABSTRACT:
Background: Since PI3K/AKT/mTOR pathway activation diminishes the effects of 
hormone therapy, combining aromatase inhibitors (anatrozole) with mTOR inhibitors 
(everolimus) was investigated.  
Patients and Methods: We evaluated anastrozole and everolimus in 55 patients 
with metastatic estrogen (ER) and/or progesterone receptor (PR)-positive breast 
and gynecologic tumors. Endpoints were safety, antitumor activity and molecular 
correlates.  
Results: Full doses of anastrozole (1 mg PO daily) and everolimus (10 mg PO 
daily) were well tolerated. Twelve of 50 evaluable patients (24%) (median = 3 prior 
therapies) achieved stable disease (SD) ≥ 6 months/partial response (PR)/complete 
response (CR) (n = 5 (10%) with PR/CR): 9 of 32 (28%) with breast cancer (n=5 
(16%) with PR/CR); 2 of 10 (20%), ovarian cancer; and 1 of 6 (17%), endometrial 
cancer. Six of 22 patients (27%) with molecular alterations in the PI3K/AKT/mTOR 
pathway achieved SD ≥ 6 months/PR/CR. Six of 8 patients (75%) with SD ≥ 6 
months/PR/CR with molecular testing demonstrated at least one alteration in the 
PI3K/AKT/mTOR pathway: mutations in PIK3CA (n=3) and AKT1 (n=1) or PTEN 
loss (n=3). All three responders (CR (n = 1); PR (n=2)) who had next generation 
sequencing demonstrated additional alterations: amplifications in CCNE1, IRS2, MCL1, 
CCND1, FGFR1 and MYC and a rearrangement in PRKDC.  
Conclusions: Combination anastrozole and everolimus is well tolerated at full 
approved doses, and is active in heavily-pretreated patients with ER and/or PR-
positive breast, ovarian and endometrial cancers. Responses were observed in 
patients with multiple molecular aberrations.
Clinical Trails Included: NCT01197170
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INTRODUCTION
Estrogens regulate growth, differentiation and 
development in many tissues including the female 
reproductive tract, bone, central nervous system, 
immune and cardiovascular systems [1-3]. The actions of 
estrogens are mediated by a group of estrogen receptors 
(ER). Aromatase, a member of the cytochrome P450 
superfamily, catalyzes the final step in the biosynthesis 
of estrogen from androgen [4]. In women with breast 
cancer, the expression of aromatase is the highest in or 
near tumor sites [5, 6]. Anastrozole (Arimidex) is a potent 
nonsteroidal aromatase inhibitor, producing approximately 
97% inhibition of estrogen biosynthesis [7].  
Several studies have evaluated combination 
approaches using hormone therapy with other targeted 
agents in patients with breast and gynecologic cancers. 
The Bolero-2 trial (trial registration ID: NCT00863655), 
a large randomized Phase III study, compared the 
aromatase inhibitor exemestane alone to a combination of 
exemestane with everolimus, an mTOR inhibitor [8]. The 
combination improved progression-free survival (PFS) 
in patients with ER and/or progesterone receptor (PR)-
positive advanced and metastatic breast cancer.  Based on 
data from the Bolero-2 trial, in July 2012 the US Food 
and Drug Administration (FDA) approved everolimus in 
combination with exemestane for use in postmenopausal 
women with hormone receptor-positive, HER2/neu-
negative, advanced breast cancer who have progressed 
on anastrozole or letrozole. Other studies have evaluated 
the aromatase inhibitor letrozole in combination with 
everolimus and have demonstrated responses in patients 
with metastatic endometrial carcinoma (trial registration 
ID: NCT01068249) [9] and breast cancer (trial registration 
ID: NCT00107016) [10].  
Research into the mechanism of endocrine 
responsiveness and resistance in breast and gynecologic 
cancers has revealed that the PI3K/AKT/mTOR pathway 
becomes activated and utilized by cancer cells to bypass 
the effects of hormone therapy [11-13]. We therefore 
investigated the use of the aromatase inhibitor anastrozole 
in combination with everolimus in patients with ER and/
or PR-positive breast and gynecologic tumors including 
ovarian and endometrial cancer (trial registration ID: 
NCT01197170) and including an analysis of molecular 
data.
RESULTS
Patients
Fifty-five women with advanced or metastatic 
breast, ovarian, endometrial, and cervical malignancies 
were enrolled. All patients received at least one dose 
of treatment. All patients were considered eligible for 
toxicity evaluation. Fifty patients were considered eligible 
for response evaluation. Five patients were ineligible 
for response evaluation because they had not reached 
restaging at the time of analysis. Demographic and clinical 
characteristics of evaluable patients are summarized in 
Table 1. The median age of patients was 57 years (range: 
24-82 years). The median number of prior therapies in 
the advanced or metastatic setting was 3 (range: 0-13). 
Twenty-three of the evaluable patients had received prior 
aromatase inhibitors. Fifteen deaths occurred, all attributed 
to disease progression. Expansion cohorts were opened for 
breast, endometrial, ovarian and cervical tumor types and 
for patients with PTEN loss and PIK3CA mutations.  
Overall Survival and Time to Treatment Failure
The median survival has not been reached after a 
median follow up of 6.1 months. At the time of analysis, 
37 of 55 (67%) were off study. The overall median TTF 
was 3.1 months (95% CI 2.1-4.1). 
Dose Escalation, DLT and Tolerance
Seven patients were enrolled at dose level 1 and 48 
at dose level 2. Two of 55 patients (4%) experienced a 
DLT. The two DLTs both occurred in expansion cohorts of 
dose level 2 and were grade 3 mucositis. The full federal 
drug administration (FDA) dose for each drug evaluated 
in dose level 2 (anastrozole 1 mg PO daily and everolimus 
10 mg PO daily) was found to be safe and well tolerated.  
Twenty-five of 55 patients (45%) experienced at 
least one drug-related toxicity. Of the 36 reported drug-
related toxicities, 25 (69%) were grade 1 or 2. The most 
common grade 1 and 2 drug-related toxicities included 
mucositis (6 patients), fatigue (4 patients), nausea/
vomiting/anorexia, elevated cholesterol, pneumonitis, 
elevated triglycerides and elevated ALT (2 patients each). 
There were 11 grade 3 toxicities at least possibly related 
to treatment including mucositis (2 patients), pneumonitis, 
hypertension, hyperglycemia, hemoptysis, weakness, 
rash, low platelets, elevated AST and decreased ANC (1 
patient each). A dose modification was required in four 
incidents for mucositis (2 patients), nausea (1 patient), and 
pneumonitis (1 patient). Two patients with pneumonitis 
(including one with grade 2 and one with grade 3 toxicity) 
were taken off study with resolution of toxicity.  
 Response Data 
Twelve of 50 evaluable patients (24%) achieved SD 
≥ 6 months/PR/CR, including 5 patients (10%) with PR/
CR: 9 of 32 patients (28%) with breast cancer (cases 1, 2, 
3, 4, 5, 6, 9, 10 and 12, Table 2); 2 of 10 patients (22%) 
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with ovarian cancer (cases 7 and 11, Table 2); and 1 of 
6 patients (17%) with endometrial cancer (case 8, Table 
2).  Neither of the 2 patients with cervical cancer achieved 
SD≥6 months/PR/CR. Five patients with breast cancer 
achieved a PR (cases 3, 4 and 5, Table 2) or CR (cases 
1 and 2, Table 2). Three patients with PR included one 
patient with a 50% decrease in disease for 11 months (case 
3, Table 2), one patient with a 44% decrease in disease for 
2 months (case 4, Table 2) and, one with a 38% decrease 
in disease for 17+ months (case 5, Table 2). The two 
patients (4%) with CRs have ongoing responses at 9+ and 
6+ months (cases 1 and 2, Table 2).  
Prior Treatment with Aromatase Inhibitors and 
Response
Twenty-three of 50 evaluable patients (46%) had 
received at least one prior aromatase inhibitor in the 
advanced or metastatic setting. Five of the 23 patients 
(22%) who had been previously treated in the metastatic 
setting with an aromatase inhibitor achieved SD ≥ 6 
months/PR/CR with the combination of anastrozole 
and everolimus, including 3 patients (13%) with PR/
CR. Twenty of 32 patients (63%) with breast cancer 
had received prior aromatase inhibitors in the advanced 
or metastatic setting. Five of the 20 patients (25%) with 
breast cancer and prior aromatase inhibitor exposure 
achieved SD ≥ 6 months/PR/CR (3 patients with PR/CR). 
Molecular Analysis and Association with Response
When archival cell blocks for patients were 
available, CLIA-certified molecular testing was performed 
for PI3K/AKT/mTOR pathway alterations. For the 
purposes of this study, we defined a PI3K/AKT/mTOR 
pathway alteration as one or more of the following: 
PIK3CA, AKT1, PTEN mutation, and/or PTEN loss 
(by IHC). Of the 12 patients who demonstrated SD ≥ 
6 months/PR/CR, 8 had molecular testing (3 of 5 with 
PR/CR). Six of the 8 patients (75%) had at least one 
alteration in the PI3K/AKT/mTOR pathway including 
PIK3CA mutations (3 patients, one of whom also had an 
AKT1 mutation) and PTEN loss (IHC) (3 patients). The 
remaining two patients (25%) with molecular testing did 
not have a direct alteration in this pathway. Three patients 
who achieved PR/CR who also had molecular testing with 
NGS demonstrated additional alterations: amplifications 
in FGFR1 (encodes for fibroblast growth factor receptor 
1, 2 patients), CCND1 (encodes for cyclin D1, also known 
as BCL1, 2 patients), CCNE1 (encodes for cyclin E1, 1 
patient), IRS2 (encodes for insulin receptor substrate 2, 
1 patient), MCL1 (myeloid leukemia cell gene, 1 patient) 
and MYC (myelocytomatosis viral oncogene, 1 patient) 
and, a re-arrangement in PRKDC (protein kinase DNA 
activated catalytic polypeptide, 1 patient).  
A total of 35 patients had molecular testing for 
at least one of the following: PIK3CA, PTEN, or AKT1 
mutation; and/or PTEN loss. Of the 35 patients tested, 
22 (63%) were positive for at least one alteration in 
the PI3K/AKT/mTOR pathway. Of 35 patients tested 
for an alteration in the PI3K/AKT/mTOR pathway, 13 
were negative. One of 13 patients (8%) attained SD ≥ 6 
months/PR/CR (this patient had a CR). By comparison, 22 
patients tested had a PI3K pathway alteration; 6 of these 
22 patients (27%) had SD≥6 months/PR/CR (2 patients 
with PR/CR) (p = 0.16).   
DISCUSSION 
Hormonal therapy is a mainstay of treatment for 
breast cancer and is an area of active investigation in 
gynecologic tumors. Strategies to augment response 
and overcome resistance to aromatase inhibitors are 
urgently needed. PI3K/AKT/mTOR pathway alterations 
are common in breast and gynecologic cancers [20-
22]. Preclinical studies have shown that suppression of 
PTEN function, or activated AKT1 expression, caused 
by activating mutations in PIK3CA or AKT1, confers 
resistance to traditional chemotherapeutic drugs as well as 
hormonal based drugs, but results in sensitivity to mTOR 
inhibitors [23, 24]. Recent studies of breast cancer patients 
treated with everolimus in combination with exemestane 
[8] and of endometrial and breast cancer patients treated 
with everolimus in combination with letrozole [9, 10] 
have shown efficacy. Based on the Phase III  study results, 
everolimus is now FDA-approved in combination with the 
aromatase inhibitor exemestane in patients with advanced, 
hormone receptor-positive breast cancer refractory to 
anastrozole and/or letrozole [8].  
Our study indicates that the combination of 
anastrozole and everolimus can be given at full approved 
doses. Tolerance was excellent with the main side effects 
being grade 1 and 2 mucositis, fatigue, nausea/vomiting/
anorexia and, grade 3 mucositis. Two patients experienced 
DLTs, mucositis in both cases. A dose reduction resulted 
in better tolerance in one patient and the other patient was 
taken off study. These results parallel those for exemestane 
[8] and letrozole [9, 10]; these hormone antagonists can be 
given safely with full dose everolimus (10 mg PO daily).  
Herein we report that 6 of 8 patients (75%) who 
experienced SD ≥ 6 months/PR/CR (3 patients with PR/
CR) on this study and on whom molecular testing was 
performed, demonstrated at least one alteration in the 
PI3K/AKT/mTOR pathway. Six of 22 patients (27%) with 
molecular alterations in the PI3K/AKT/mTOR pathway 
achieved SD ≥ 6 months/PR/CR, including 2 patients (9%) 
with PR/CR. Our results support and expand on those 
previously reported [21, 25]. Indeed, 12 of 50 heavily 
pretreated patients (24%) with breast or gynecologic 
tumors achieved SD ≥ 6 months/PR/CR with anastrozole 
and everolimus, including 5 patients (10%) with PR/CR. 
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These results are consistent with the SD ≥ 6 months/PR/
CR rates of 20 to 30% previously reported by our group 
in patients treated with matched phase I therapy [21, 
25]. Our response rates are slightly higher than those 
reported in Bolero-2 [8], but our patient numbers are also 
smaller. Further, some of our patients with breast cancer 
did not receive prior aromatase inhibitors. The number 
of patients with endometrial cancer are small, but the 
observed activity is lower than reported in the letrozole/
everolimus combination in this tumor type [9]. Regarding 
correlation with molecular aberrations, we found that 
six of eight responders tested had pathway aberrations. 
These aberrations included abnormalities in PIK3CA, 
PTEN and AKT, consistent with the diversity of genes 
that can activate the PIK3CA/AKT/mTOR pathway.  On 
the other hand, only 27% of patients with these pathway 
abnormalities responded.  These data are consistent with 
data recently presented by Hortobagyi et al. [26], where 
patients with either no or only one molecular aberration in 
the PI3K/AKT/mTOR pathway had better outcomes with 
exemestane and everolimus than did patients with multiple 
aberrations. On the other hand, three of our patients with 
CR or PR showed multiple aberrations indicating that their 
presence does not rule out response.   
A total of 3 patients who achieved PR/CR had NGS 
testing. These patients demonstrated numerous alterations 
including: CCNE1, CCND1, FGFR1, IRS2, MCL1, 
and MYC amplifications and a PRKDC re-arrangement, 
as well as TP53 mutations (cases 1, 3 and 5, Table 2). 
CCNE1 and CCND1 code for cyclin D1 and cyclin E1, 
respectively, which are proteins that help control the 
transition of cells from G1 to S phase during proliferation 
[27]. Both of these proteins are regulated by GSK-3β, 
which is directly phosphorylated by AKT [28]. MYC 
is a regulator gene that codes for a transcription factor 
involved in cell proliferation and is also directly regulated 
by GSK-3β [29]. Insulin receptor substrates (IRS1 and 
IRS2) are proteins that dock to IGFR receptors to recruit 
other factors such as the p85 regulatory subunit of PI3K, 
thereby leading to activation of the PI3K/AKT/mTOR 
pathway [30]. Fibroblast growth factor receptors (FGFR) 
bind to growth factors (FGF) involved in angiogenesis. 
Activation of FGFR induces PI3K and AKT activities 
through recruitment and tyrosine phosphorylation of the 
docking protein Gab1 that results in the activation of PI3K 
[31]. MCL1 codes for a protein that enhances cell survival 
by inhibiting apoptosis. Control of MCL1 stability by 
GSK-3β is an important mechanism for the regulation of 
apoptosis by AKT [32]. Tumor Protein 53 (TP53) codes 
for a tumor suppressor (p53) that regulates cell cycle. AKT 
influences the activity of p53 through phosphorylation 
of the p53-binding protein MDM2 [33]. Protein kinase, 
DNA-activated, catalytic polypeptide (PRKDC) codes for 
a catalytic subunit of the DNA-dependent protein kinase, a 
member of the PI3K family [34]. The presence of multiple 
gene aberrations may reflect increased genetic instability 
and poor patient prognosis [35]; however, the combination 
of anastrozole and everolimus was beneficial for each of 
these three patients.  One of the patients with a durable 
CR (case 1, Table 2) had NGS testing and demonstrated 
a TP53 mutation as well as amplifications in CCNE1, 
IRS2, a protein important for insulin receptor signaling 
[36], and MCL1, a gene that plays a role in regulating 
cell-fate decisions [37]. The latter results suggest that 
CR can be achieved in the absence of a direct alteration 
in the PI3K/AKT/mTOR pathway, even when multiple 
molecular aberrations are present. However, some of the 
above genes may modulate the PIK3CA/AKT/mTOR 
axis perhaps explaining in part the response [31, 38-43]. 
Systems biology bioinformatics approaches will be needed 
to determine whether or not multiple aberrant signals in 
patients with metastatic tumors converge on pathways 
such as PI3K/AKT/mTOR pathway, and are hence 
actionable.   
Our results suggest that patients can obtain salutary 
effects including CR (and PR) despite the presence of 
multiple alterations; however, should relapse occur 
in any of these patients, it might be explained by the 
additional alterations eventually leading to resistance. 
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Fig 1: 3D Waterfall. Best radiologic response by RECIST and months on treatment (N = 50 patients).  (+) Patients positive for alterations 
in PI3K/AKT1/mTOR pathway.
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It is not surprising that patients with advanced disease 
have multiple molecular alterations, as this observation is 
consistent with previous literature reports of heterogeneity 
within and between tumors [44-46]. 
There are several limitations to our study. Whether 
the responses observed are due simply to the inhibition 
of the PI3K/AKT/mTOR pathway by everolimus or due 
to hormone modulation by aromatase inhibition alone 
(especially in those patients not previously treated with 
anastrozole) or contribution from both is unknown, as 
this was not a randomized study. However, it should be 
noted that the rate of SD ≥ 6 months/PR/CR was similar 
in patients who had failed prior aromatase inhibition 
therapy (5 of 23 patients, 22%) versus those who had not 
had aromatase inhibition (7 of 27 patients, 26%), which 
suggests that everolimus contributed to those responses. 
Another potential limitation of this analysis is that a 
majority of our patients had breast cancer, and that the 
combination of an aromatase inhibitor and an mTOR 
inhibitor has recently been demonstrated to be effective. 
However, we provide correlative molecular data and 
show responses in endometrial and ovarian cancers, as 
well as breast cancer. Further, we show that the activity in 
breast cancer is seen with anastrozole and therefore is not 
limited to exemestane (as used in previous studies) [8]. 
Additional limitations of our study stem from the fact that 
only a subset of patients had next generation sequencing. 
Furthermore, comparison of MD Anderson CLIA 
“hotspot” testing versus next generation sequencing was 
also performed in only limited number of patients. It is 
possible that other mutations exist in some of the patients 
tested by “hotspot” analysis, and were not discerned by 
this type of testing. As an example, a recent study in breast 
cancers has identified additional driver mutations in AKT1 
that are not located in hotspot regions frequently tested 
[47]. We also had molecular data from only one time point; 
pre- and post-tissue analyses would be more informative 
to elucidate resistance patterns.  Future investigations 
should emphasize molecular analysis so that biological 
correlates of clinical response can be identified. Finally, 
our patient numbers were relatively small. Therefore, these 
results must be interpreted in this context and considered 
hypothesis generating. 
In conclusion, our study demonstrates that full doses 
of the aromatase inhibitor anastrozole and the mTOR 
inhibitor everolimus can be given for prolonged periods of 
time (longest so far = 17 months) with excellent tolerance. 
A subset of heavily pretreated patients with breast, ovarian 
and endometrial cancer achieved SD ≥ 6 months/PR/CR. 
SD ≥ 6 months/PR/CR was seen in 27% of patients with 
molecular alterations in the PI3K/AKT/mTOR pathway. 
Patients with multiple molecular alterations still benefited 
from therapy.  Further exploration of this combination 
in larger cohorts of patients with breast and gynecologic 
tumors and in-depth analysis of molecular correlates is 
warranted.  
PATIENTS AND METHODS
Patients
The study enrolled adult patients with 
pathologically-confirmed advanced or metastatic 
cancer. Patients were required to have tumors that 
demonstrated ER and/or PR-positive disease (positivity by 
immunohistochemistry staining ≥ 1% based on reported 
guidelines for breast cancer) [14]. For women, only 
those who were postmenopausal or premenopausal and 
receiving a gonadotropin-releasing hormone agonist were 
eligible. All patients had an Eastern Cooperative Oncology 
Group (ECOG) performance status score of 0 to 2. Other 
criteria included adequate neutrophil counts (≥ 1,000/mL), 
platelets (≥ 50,000/mL), creatinine (≤ 2 × upper limit of 
normal), bilirubin (≤ 2.0), alanine aminotransferase 
(ALT) (≤ 3 × upper limit of normal with the exception of 
patients with liver metastasis in whom ALT ≤ 5 × upper 
limit of normal and bilirubin ≤ 3 × upper limit of normal). 
Patients provided written informed consent according to 
institutional guidelines. The study was approved by the 
Institutional Review Board (IRB).    
Study Design and Treatment
This was a single institution, open-label, dose-
escalation study, with a standard 3+3 design. The study 
allowed an additional (optional) three patients at any dose 
level in order to provide flexibility for enrollment and 
additional safety or correlative data. Endpoints were to 
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establish safety and preliminarily assess antitumor efficacy 
and molecular correlates.  
Each treatment cycle was 28-days with both drugs 
given daily. Cycles were consecutive with no treatment 
breaks. Patients were initially treated at dose level 1 
(anastrozole 1 mg PO daily and everolimus 5 mg PO 
daily) and if no serious toxicities were observed the dose 
was escalated to dose level 2 (anastrozole 1 mg PO daily 
and everolimus 10 mg PO daily). Dose level 2 represents 
the full approved dose of each drug. Once the safety of 
dose level 2 was established, additional patients were 
enrolled at that level.  
If a response was observed in a particular tumor 
subtype, study cohorts were expanded to include up to 
an additional 14 participants with that specific tumor 
type. For the purpose of adding up to 14 additional 
participants, a tumor (including, but not limited to tumor 
type, histologic subtype or genomic subtype) response was 
defined as one of the following: (1) stable disease (SD) ≥ 
6 months; or (2) decrease in measurable tumors ≥ 20% by 
RECIST criteria.  
Assessment of Safety and Efficacy
Treatment continued until unacceptable toxicity or 
disease progression occurred.  Dose delays and reductions 
were at the discretion of the treating physician. Toxicities 
were graded based on the Common Terminology Criteria 
for Adverse Events (CTCAE v4.0). Dose limiting 
toxicities (DLTs) were defined as adverse events (AEs) 
related to study agents that occurred during the first cycle 
of treatment with an attribution of possible, probable, 
or definitely related to therapy and fulfilling one of the 
following requirements: grade 4 neutropenia lasting > 
7 days, febrile neutropenia, platelet count <25,000/mm 
lasting >7 days, any grade 4 or toxicity, any grade 3 
toxicity (excluding nausea, vomiting and diarrhea unless 
it persisted despite optimal treatment).  
Responses were assessed after three cycles (about 
12 weeks) or earlier at the discretion of the treating 
physician. All radiological tests were assessed by an MD 
Anderson radiologist.  In addition, results were reviewed 
in a departmental tumor measurement clinic and by the 
attending physician. RECIST criteria were used for 
progressive disease (PD), stable disease (SD), partial and 
complete responses (PR and CR).  
Molecular Assays for Biological Markers: 
PIK3CA, AKT1, PTEN mutations, and PTEN loss
Clinical Laboratory Improvement Amendment 
(CLIA) certified mutational and/or immunohistochemistry 
assays were performed, when tissue was available, 
for PIK3CA, AKT1, and PTEN mutations, and PTEN 
expression.  The tests were done within the Division of 
Pathology and Laboratory Medicine at MD Anderson. 
Archival formalin-fixed, paraffin-embedded tissue blocks 
or tissue from fine-needle aspiration or surgical biopsies 
were used for mutational analysis. DNA was extracted 
and analyzed using a polymerase chain reaction (PCR)-
based DNA sequencing method for PIK3CA mutations in 
codons [c] 532-554 of exon 9 (helical domain) and c1011-
1062 of exon 20 (kinase domain) [15], which included 
the mutation hot spot region of the PIK3CA proto-
oncogene by Sanger sequencing following amplification 
of 276 bp and 198 bp amplicons, respectively, utilizing 
primers designed at MD Anderson. For AKT1 and PTEN 
mutations, similar methods were used. Codons 17, 1173, 
and 179 were examined for AKT1 mutations, and for 
PTEN, the entire coding sequence of exons 1 through 9 
were examined as previously described [16]. PTEN loss 
was assessed using a Dako antibody (Carpinteria, CA, 
USA) as previously published [16, 17].
Evaluation of HER2/neu amplification, estrogen 
and progesterone receptor status 
Under CLIA conditions, immunohistochemistry was 
used to measure of HER2/neu, estrogen and progesterone 
receptors. Estrogen and progesterone receptors were 
assessed using antibody 6F11 (Novocastra Laboratories, 
Ltd., Newcastle Upon Tyne, UK). Alternatively, 
fluorescence in situ hybridization (FISH) was used to 
measure the copy number of HER2/neu.  
Next-Generation Sequencing
Genomic libraries were captured for 3230 exons in 
182 cancer-related genes plus 37 introns from 14 genes 
often rearranged in cancer and sequenced to average 
median depth of 734× with 99% of bases covered >100× 
(Foundation Medicine, Cambridge, MA, USA). 
Statistical Analysis
Descriptive statistics are provided for all endpoints 
using SPSS v.19 (Chicago, IL, USA). Continuous 
measurements were summarized using mean, standard 
deviation, median, range, number of patients, and 
percentages. Time to treatment failure (TTF) and overall 
survival were calculated using the method of Kaplan and 
Meier [18, 19] in months, from date of first treatment 
dose to the date of last treatment dose or death from any 
cause, whichever came first. Patients still on study at the 
time of data analysis were censored at the time of last 
assessment for TTF. For survival, patients still alive at 
the time of analysis were censored at that time point. A 
three-dimensional waterfall plot depicting best RECIST 
responses by percent and time on therapy is presented in 
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Figure 1.
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